Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809135 | 0.86 | GABRP (0.46) | ADORA1ADORA2AADORA3ADORA2BDAGLA | |
| SCHEMBL3048357 | 0.83 | DAGLA (0.54) | HPGDMAPTFPR2DAGLALTB4R | |
| SCHEMBL630546 | 0.78 | RXRA (0.37) | ADORA1ADORA2AHPGDADORA3ADORA2B | |
| SCHEMBL12419638 | 0.78 | S1PR1 (0.33) | ADORA1ADORA2AADORA3ADORA2BS1PR1 | |
| SCHEMBL3045258 | 0.75 | FPR2 (0.40) | HPGDMAPTFPR2DAGLALTB4R | |
| SCHEMBL24105968 | 0.73 | S1PR1 (0.46) | ADORA1ADORA2AADORA3ADORA2BS1PR1 | |
| SCHEMBL3047857 | 0.73 | KMO (0.40) | HPGDKDM4ELMNAS1PR1MAPT | |
| SCHEMBL1808837 | 0.73 | FPR2 (0.38) | HPGDPDE3BPDE3AP2RY12LMNA | |
| SCHEMBL3046311 | 0.73 | FPR2 (0.42) | HPGDKDM4EPDE3BPDE3AP2RY12 | |
| SCHEMBL24258815 | 0.73 | HPGD (0.39) | HPGDPDE3BPDE3AP2RY12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947841-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947841-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | ELI LILLY AND COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | ELI LILLY AND COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | ELI LILLY AND COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1658285-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1658285-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1658285-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019212-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | ADORA1 958/4885ADORA2A 2377/4885HPGD 4158/4885 |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | ADORA1 1308/4885ADORA2A 2409/4885HPGD 3808/4885 |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | ADORA1 1308/4885ADORA2A 2409/4885HPGD 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.